Biologic Therapies
Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis
... ease activity scores to evaluate the efficacy of such biologic therapies even less adequate. On the other hand, some extra- articular manifestations are often major variables in clinical decision-making ...
12
What is the impact of biologic therapies on common co morbidities in patients with rheumatoid arthritis?
... The impact of biologic therapies on outcomes for pa- tients has been substantial in terms of their disease con- trol. In addition it appears that TNFi at least can improve some of the burden of comorbidity ...
10
Human rheumatoid arthritis tissue production of IL 17A drives matrix and cartilage degradation: synergy with tumour necrosis factor α, Oncostatin M and response to biologic therapies
... Targeted biologic therapies including anti-TNF-α have advanced the treatment of inflammatory arthritis. Some patients, however, do not respond, highlighting the need for new therapeutic targets. The ...
12
Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America
... two biologic surveys in 2011–2013, the 2013–16 CARRA meetings were used to discuss biologics for refractory JDM as re- ported in the literature [27–44] and beginning discus- sions of a future consensus treatment ...
8
Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies
... following: glucocorticoids, which decrease inflammation and reduce immune system activity, but are limited by a high side effect profile; conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), which ...
7
<p>Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis</p>
... a biologic agent (ie, adalimumab, certolizu- mab, etanercept, golimumab, in fl iximab, ixekizumab, secukinumab, or ustekinumab) for treatment of psoriasis between January 1, 2015, and December 31, ...of ...
9
An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review
... Initial treatment of uveitis in BD depends on both the severity and location of inflammation, highlighting the im- portance of precise diagnosis [33]. The aim of treatment is to control the inflammatory process in order ...
12
Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis
... IV biologic therapy was indicated (ie, AS, CD, PsA, PsO, RA, or UC); current treatment with an IV bio- logic; and having received at least three infusions of the pre- scribed IV ...
9
Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor α inhibitors
... Several authors have reported that efficacy estimates of TNF- a inhibitors in patients naïve to biologic treatment are consistently different in RCTs and observational stu- dies [59,60]. To determine whether the ...
15
BIOLOGIC ARMAMENTARIUM IN PSORIASIS
... conventional therapies. The introduction of biologic therapy has a great impression on psoriatic treatment duration and enhanced quality of life in psoriasis ...new biologic therapies are ...
8
Biologic adjuvants for fracture healing
... of biologic therapies that enhance bone repair in fractures and ...the biologic agents that can enhance bone repair and either are clinically available or are being assessed in clinical ...
13
Biologic therapy for autoimmune diseases: an update
... of biologic therapies as an adjunct to disease- modifying anti-rheumatic drugs (DMARDs) for the treatment of autoimmune and rheumatologic diseases is rapidly expanding, owing to the good efficacy and safety ...
12
Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis
... Findings derived from the present analysis indicate that treatment with tocilizumab allows a significantly greater proportion of patients to attain clinical benefit within 6 months compared to other biologic ...
11
Non-eosinophilic asthma: current perspectives
... forthcoming biologic therapies specifically target type 2 asthma phenotypes, such as uncontrolled severe eosinophilic or allergic asthma, there is a dramatic lack of effective treatments for uncontrolled ...
15
Evaluation of psoriasis patients’ attitudes toward benefit–risk and therapeutic trade-offs in their choice of treatments
... The choice survey is intended to simulate decisions in clinical practice, but of course it does not have the clinical or emotional consequences of actual decisions. Differences can arise between stated and actual ...
10
Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making
... and rheumatologists prioritize very different factors when making decisions regarding treatments. As such, it is critical to understand better the dialogue that occurs between patients and rheumatologists. When examining ...
12
Experiences of mobility for people living with rheumatoid arthritis who are receiving biologic drug therapy: implications for podiatry services
... biologic therapies. Four key themes emerged from the data: 1) Life before biologic treatment, depicted in accounts as a negative experience characterised by painful and disabling symptoms and ...
9
Biologic Width Dimensions in Diseased And Healthy Periodontium - A Clinico- Radiographic Study
... clinical biologic width in healthy subjects was significantly higher than mean clinical biologic width in subjects with chronic generalized periodontitis (p < ...clinical biologic width in group A ...
7
Biologic Width - The No Encroachment Zone
... of biologic width was less understood till very recently but the growing clinical experience and better diagnostic skills of today has helped us to understand the intricacies of this concept and the need for its ...
8
Biologic agents in juvenile spondyloarthropathies
... and biologic agents have been used with conflicting results in the treatment of these complex ...Other biologic agents, such as abatacept, tocilizumab and rituximab, have been insufficiently studied and ...
8